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Detriment to cognitive function is suggested by some studies, but 
whether this risk changes based on age is unknown. The purpose 
of this project was to determine patterns of practice of PCI for 
both limited stage SCLC (LS-SCLC) and extensive stage SCLC (ES-
SCLC) across Canada with a focus on how age affects 
recommendations in clinical practice. 
Methods and Materials: A survey was created in English and 
French. It was approved and distributed through Canadian 
Association of Radiation Oncology (CARO) to all its radiation 
oncologist members. Answers were collected anonymously using 
Google Forms over a five week period. Descriptive statistics were 
used to analyze responses. 
Results: Fifty-seven responses were collected with 
representation from all CARO regions. Ninety-eight percent of 
respondents routinely would recommend PCI for LS-SCLC and 78% 
for ES-SCLC. For LS-SCLC, age was an independent factor for 
recommending PCI for 52% of respondents, and 65% used an age 
cut off of 80 – 84 years. For ES-SCLC, only 46% of respondents 
would consider age when recommending PCI, and 48% of those 
also used 80 – 84 years as the cut off. 85% justified this cut point 
based on poor patient outcome in their own or a colleague’s 
experience. Forty-two percent of respondents who didn't use an 
age cut off indicated that a patient's performance status was a 
more relevant criterion. 
Conclusions: Based on the consensus opinion from this survey, 
we would suggest PCI for SCLC should be offered to patients with 
acceptable performance status under 80 years of age. For 
patients 80 years and older, caution is recommended. 
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Purpose: The current standard of care for unresectable locally 
advanced Stage III non-small cell lung cancer (NSCLC) is 
chemoradiotherapy. However, there is no established consensus 
for the optimal chemotherapy regimen. We designed a Phase I 
study of docetaxel and cisplatin (DC) chemotherapy with 
concurrent thoracic radiotherapy (RT) followed by consolidative 
DC for locally advanced NSCLC. The primary objective of this 
study is to determine optimal concurrent and consolidative DC 
doses, with secondary objectives to describe associated 
toxicities. 
Methods and Materials:  Patients with histologically or 
cytologically proven and unresectable Stage IIIA or IIIB (dry) 
NSCLC were eligible for this single-institution research-ethics 
board approved study. In the concurrent cycles with thoracic RT, 
C was given every three weeks (fixed at 75mg/m2) and D given 
weekly. The starting dose of D was 20 mg/m2 weekly escalated 
in cohorts of three to define the maximum tolerated dose. RT 
was prescribed to a dose of 60 Gy in 30 fractions. This was 
followed by two cycles of consolidative DC, which were dose 
escalated if concurrent chemoradiotherapy was tolerated. 
Evaluation for dose limiting toxicities was performed on a weekly 
basis during RT. Tumour response was characterized through the 
RECIST criteria. Actuarial outcomes of overall survival (OS) and 
progression-free survival (PFS) were estimated using Kaplan-
Meier analysis. 
Results:  Between September 2004 to June 2014, 26 patients 
were enrolled. One patient did not receive protocol-specified 
treatment due to metastatic disease on baseline imaging. Of the 
eligible patients, 18 had Stage IIIA and seven had Stage IIIB 
disease. The median OS all patients was 33.6 months (95% CI 
15.8-71.6). Median PFS was 17.0 months (95% CI 9.2-26.3) with 
median follow up of 26.6 months (range 0.43 -110.8). The 
majority of patients (19/26) completed both phases of treatment 
and most received concurrent D at 20mg/m2 weekly. Eight 
patients tolerated dose escalation of posterior consolidative C or 
D. Twelve patients experienced Grade 3 toxicities (five 
esophagitis, one pneumonitis, three nausea, one leukopenia, and 
two neutropenia). Three patients had Grade 4 neutropenia. No 
patients died due to early or late treatment toxicities. Complete 
response, partial response, and stable disease were observed in 
one, 16 and four patients, respectively. Five patients underwent 
surgical resection, and three of five did not have evidence of 
residual disease. 
Conclusions:  Cisplatin and docetaxel (DC) chemotherapy with 
concurrent radiation treatment followed by consolidative DC 
achieved promising results in the treatment of Stage III NSCLC in 
light of reported outcomes from RTOG 0617 (standard arm 
median PFS 11.8, OS 28.7 months). However, treatment 
toxicities should be considered. The dose finding results of this 
study will inform the design of Phase II/III trials. 
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Purpose: Cutaneous squamous cell carcinoma (cuSCC) accounts 
for approximately 30% of all skin cancers and is one of the most 
common cancers in North America. The standard treatment for 
locally advanced cuSCC is surgery followed by adjuvant 
radiotherapy (RT). Patients presenting with locally advanced or 
recurrent disease are often elderly or immunosuppressed, and 
may be medically inoperable or technically unresectable. These 
patients are traditionally treated with radiotherapy alone since 
adding concurrent chemotherapy may not be well tolerated by 
this group. The risk of locoregional recurrence is about 40% for 
RT alone, compared to 15% in those treated by surgery and RT. 
Cetuximab is an antagonistic monoclonal chimeric IgG1 antibody 
that binds to the epidermal growth factor receptor (EGFR). EGFR 
overexpression in cuSCC varies between 43–100% of patients. 
Small, single institutional studies have retrospectively reported 
synergistic activity when combining Cetuximab and RT (CRT) for 
the treatment of metastatic or unresectable cuSCC. In 
preparation for a larger Phase II study, this project prospectively 
identified patients with unresectable cuSCC who were 
candidates for CRT. 
Methods and Materials: Three patients have been treated with 
CRT in the last 18 months. Data regarding patient outcome and 
tolerability was collected prospectively. Cetuximab was 
delivered weekly, with the first dose timed as a loading dose (400 
mg/m2) seven days prior to the initiation of radiotherapy. 
Concurrent with radiation, weekly doses of cetuximab were 
administered at a dose of 250 mg/m2. Radiation doses varied 
between patients (5500 cGy/22#, n = 1, and 6600 cGy/30#, n = 
2). 
Results: The median age in our cohort was 85 years. All were 
male patients, with Karnofsky performance scores ≥ 60. Two 
patients were treated for primary SCC (T3N0M0 and T3N1M0) 
while the third patient was treated for recurrent disease. 
Notably, one patient presented with Waldenstrom’s 
macroglobulinemia. Treatment was well tolerated, and felt to 
be comparable to treatment with RT alone. One patient 
developed a Grade 2 acneiform skin reaction likely related to 
cetuximab. One patient developed an acute coronary syndrome 
(Grade 3), most likely unrelated to therapy. Two patients had a 
complete response to treatment. The first patient is in remission 
for 18 months and the second patient is in remission for 12 
months. The third patient completed CRT two months ago and is 
waiting for reassessment.  
Conclusions: Despite the frailty of our cohort, CRT was well 
tolerated and produced exceptional clinical outcomes. 
Limitations to this study include its small sample size and non-
randomization. This study will serve as the basis for a larger, 
prospective, randomized Phase II study which is now in 
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Purpose: A variety of dose/fractionation schemes are used for 
adjuvant radiotherapy (RT) in node positive (Stage III) 
melanoma. A prospective randomized study of adjuvant nodal 
radiation for high-risk Stage III melanoma used 2.4 Gy x 20 
fractions in four weeks. The largest retrospective series to date 
used a hypofractionated scheme of 6 Gy x 5 fractions over 2.5 
weeks. No randomized comparison of these has been reported. 
At our institution, either fractionation is used based on physician 
and patient preference. We sought to compare clinical outcomes 
using hypofractionated and conventional radiotherapy for node 
positive melanoma. 
Methods and Materials: Patients who received adjuvant 
radiation for node positive melanoma between 2009 and 2014 
were included. Kaplan–Meier estimates of overall survival (OS) 
and 95% confidence intervals (CI) were obtained. Logistic 
regression was used to explore the association between patient, 
tumour and treatment factors for the outcomes of these 
patients. 
Results: Forty-one patients were included in the final analysis. 
Median follow up was two years. Sixty-one percent of patients 
were treated with hypofractionated radiotherapy (6 Gy x 5 for 
23 patients and 6 Gy x 6 for two patients) and the remainder 
received conventional fractionation 40-60 Gy in 15-30 fractions). 
Treatment sites included the axilla (39%), groin (29%) and 
head/neck (32%). No significant differences in stage, number of 
involved nodes, largest node, nodal location, or extracapsular 
extension were present between the two groups. Comparing the 
hypofractionated versus conventional groups, there was no 
significant difference in regional control (76 versus 84%), distant 
control (48 versus 44%) or overall survival (67 versus 62%). 44% 
were referred to a specialty clinic for management of 
lymphedema in the hypofractionated group versus 19% in the 
conventional group (HR 2.56, 95% CI 0.85-7.68, p = 0.094). 
Conclusions: Hypofractionated and conventional radiotherapy 
results in similar rates of disease control at two years in node 
positive melanoma. A trend towards higher referrals for 
lymphedema management was observed in the hypofractionated 
group. Future work should prospectively compare outcomes and 
toxicity for giving patients best advice for hypofractionation 
compared with standard treatment. 
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Purpose: Stage III cutaneous melanoma incorporates a 
heterogeneous patient group with node positive disease. 
Adjuvant radiotherapy decreases regional recurrence but its use 
is sporadic, in part due to a high competing risk of distant failure. 
This study aimed to assess our institutional practice patterns, 
evaluate clinical outcomes post radiotherapy, and identify risk 
factors for distant metastases in Stage III melanoma patients. 
Methods and Materials: Patients who received adjuvant 
radiation for node positive melanoma between 2009 and 2014 
were included. Kaplan-Meier estimates of overall survival (OS) 
and 95% confidence intervals (CI) were obtained. Logistic 
regression was used to explore the association between patient, 
tumour and treatment factors for the outcomes of these 
patients. 
Results: Forty-one patients were analyzed. Median follow up was 
two years. Sixty-one percent presented with palpable nodal 
disease. Sixty-six percent had a sentinel lymph node procedure 
prior to completion nodal dissection. Patients had an average of 
three involved lymph nodes and 23 total lymph nodes removed. 
Extracapsular extension was present in 51% of patients. Sixty-one 
percent of patients received hypofractionated radiotherapy (30 
Gy/5 fractions or 36 Gy/6 fractions over 2.5-3 weeks) versus 39% 
who received conventional fractionation (typically 48 Gy/20 
fractions). Regional radiation targets included the axilla (39%), 
head and neck (32%) and groin (29%). At two years, regional 
control was 82% and distant control was 46%. Median overall 
survival was 3.7 years. All patients who experienced a regional 
failure post-RT developed distant metastases and died of 
melanoma. All patients who were free of distant failure had 
regional control. Development of distant metastases was strongly 
associated with extracapsular extension (HR 4.0, 95% CI 1.8-8.7, 
p < 0.0001). T-stage, N-stage, RT dose, neurotropism, nodal size, 
location and number involved were not associated with regional 
or distant control. 
Conclusions: Patients who receive adjuvant radiotherapy for 
node positive melanoma have high rates of regional control but 
are prone to distant failure. Regional failure is a harbinger of 
distant disease. Extracapsular extension also predicts distant 
failure in this population. 
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Purpose: Prostate cancer resulted in approximately 4100 deaths 
in Canada in 2015. The advent of new systemic agents for 
treatment of metastatic castration-resistant prostate cancer 
demonstrating overall survival benefits has changed the 
landscape of care, and may impact the demand for and provision 
of palliative radiation to bone (PRTB) in this population. The 
purpose is to describe the use of PRTB in patients who died of 
prostate in British Columbia between 2003 and 2015. 
Methods and Materials: All patients that died of prostate cancer 
in the time period were identified from a population-based 
provincial cancer registry. Exclusion criteria included: other sites 
of cancer diagnosis, lack of adenocarcinoma histology, RT to non-
bone sites or of non-palliative intent. Patient and treatment 
characteristics were analyzed using SAS. PRTB use for the first 
and last courses was calculated by year of death, overall, and by 
region. Survival was calculated for the following: from first 
course of PRTB to death, from last course of PRTB to death, and 
by treatment year. To assess the adequacy of provision of PRTB 
in this population, the geographical distribution of the incidence 
of prostate cancer was compared with the treatment frequency 
across the province.  
Results: Out of 23,260 prostate cancer patients who died 
between 2003 and 2015, 5701 had prostate adenocarcinoma as 
their only primary cancer diagnosis. The median age at the time 
of death was 81 and median survival after diagnosis was 5.2 
years. Utilization of PRTB prior to death was 38.6% (2203 
patients), with a trend to increase overtime from 29% in 2003, to 
44% in 2015. Multiple courses of PRTB were frequent, with 
patients receiving two, three, four or more courses of PRTB in 
25%, 13%, and 14% of cases respectively. Survival after first 
course of PRTB to prostate cancer death was 38.6% at one year, 
and 2.3% at five years, and a median of 8.5 months. Median 
survival after first course of PRTB increased slightly over the 
study years for those dying of prostate cancer from 8.2 months 
in 2003-5 to 9.4 months in 2013-15 (p = 0.04). For last course of 
PRTB, 2% were treatment within the last four weeks of their life. 
Use of PRTB varied with region and was lower in some rural 
areas.  
